Insider Trading February 20, 2026

Gentex VP Disposes Nearly $500k in Stock While Retaining Substantial Stake

Sale by Vice President Matthew Chiodo coincides with prior share grants and recent quarterly results that prompted an analyst price-target cut

By Hana Yamamoto GNTX
Gentex VP Disposes Nearly $500k in Stock While Retaining Substantial Stake
GNTX

Gentex Vice President of Sales Matthew Chiodo sold 19,827 shares on February 17, 2026, for about $496,170, while also recording zero-price acquisitions and tax-related share withholdings in filings with the SEC. The transactions leave Chiodo with 47,148 shares. Separately, Gentex posted a slight EPS beat but a marginal revenue shortfall for Q4 2025, prompting UBS to lower its price target to $25 and affirm a Neutral rating.

Key Points

  • Insider transaction: Gentex VP of Sales Matthew Chiodo sold 19,827 shares on February 17, 2026 for approximately $496,170 at $25.025 per share.
  • Form 4 activity also records zero-price acquisitions of 28,269 shares (Feb 17) and 12,047 shares (Feb 19), and 15,751 shares used to cover taxes at $24.89; Chiodo now directly holds 47,148 shares.
  • Company performance context: Q4 2025 EPS of $0.43 beat the $0.42 estimate by 2.38%, revenue of $644.4 million missed the $650.81 million forecast by 0.98%, and UBS lowered its price target to $25 while keeping a Neutral rating.

Gentex Corporation reported a notable insider transaction involving Vice President of Sales Matthew Chiodo in filings submitted to the U.S. Securities and Exchange Commission. According to the Form 4, Chiodo sold 19,827 shares of company stock on February 17, 2026, in a transaction valued at approximately $496,170, with each share sold at $25.025.

The filing provides additional detail on related movements in Chiodo's holdings. On February 17 and February 19, the Form 4 shows that Chiodo acquired 28,269 shares and 12,047 shares of Common Stock respectively, each listed at a price of $0. The filing further indicates that 15,751 shares were applied to satisfy tax obligations at a price of $24.89 per share.

After accounting for the sale, the zero-price acquisitions and the tax-related share withholding, Chiodo's direct ownership in Gentex stands at 47,148 shares. At the time the filing was noted, Gentex shares were trading at $23.97 and the company had a market capitalization of $5.25 billion.

Independent platform analysis cited in the filing materials indicates that Gentex appears undervalued at current market levels. The same source also highlighted the company’s record of sustained shareholder returns via dividends, noting 24 consecutive years of dividend payments and a current yield of 2.0%. The platform referenced in the filing offers a comprehensive research report for Gentex along with coverage of more than 1,400 other U.S. equities.

These insider activity details arrive against the backdrop of Gentex’s recently reported fourth-quarter 2025 results. The company posted earnings per share of $0.43, a modest beat versus the $0.42 forecast, representing a 2.38% upside to consensus. Revenue for the quarter was $644.4 million, which missed the expected $650.81 million by 0.98%.

Following the quarterly release, UBS adjusted its outlook by lowering its price target for Gentex to $25.00 from $26.00, while retaining a Neutral rating on the shares. In its commentary, UBS noted that although the quarter faced certain one-time headwinds, results were "better than headline" and included an 8% beat on EBIT.

Investors and market watchers will track how the insider transaction, the firm’s dividend history and the recent quarterly figures factor into sentiment and valuation discussions for Gentex moving forward.


Clear summary

Matthew Chiodo sold 19,827 Gentex shares on February 17, 2026 for about $496,170 at $25.025 per share. The Form 4 also records the acquisition of 28,269 and 12,047 shares at $0 on February 17 and 19, respectively, and 15,751 shares surrendered to cover taxes at $24.89. Post-transactions Chiodo owns 47,148 shares. Separately, Gentex’s Q4 2025 results showed a slight EPS beat and a small revenue miss, prompting UBS to cut its price target to $25 while keeping a Neutral rating.

Risks

  • Analyst reassessment: UBS lowered its price target for Gentex to $25 from $26, reflecting changed near-term expectations and creating potential price pressure for shareholders and market participants.
  • Revenue shortfall: Q4 2025 revenue missed estimates by 0.98%, an uncertainty that could affect near-term performance perceptions among investors and analysts.
  • Insider selling and tax-related share dispositions: The combination of a material sale and shares used to cover tax obligations may be viewed by some market participants as adding uncertainty to near-term insider commitment signals.

More from Insider Trading

Espey MFG Director Executes Option Exercises, Sells Shares Worth About $130K Feb 20, 2026 Friedman Industries CEO Buys 600 Shares; Company Confirms Dividend and Expands Credit Line Feb 20, 2026 Avidbank Director Rosinus Disposes $126,027 in Stock; Company Posts Mixed Q4 Results Feb 20, 2026 Rogers Corp SVP Michael Reed Webb Sells Shares as Company Posts Strong Q4 Results Feb 20, 2026 Clearfield Director Disposes $115K in Stock as Company Reports Mixed Q1 Results Feb 20, 2026